Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

Key facts

Study ID

NCT00366262

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

Starts

2006-06-01

Expected to finish

2007-03-01

Last updated by the study team

2008-08-05

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men or women of nonchildbearing potential, aged 18 to 60 years.

You may not qualify if…

• Abnormal baseline endoscopy.
• Positive Helicobacter pylori serology.

Where it is running

• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.